Water Vapor Ablation for Prostate Cancer: Long-Term Registry

The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).

Inclusion Criteria: * Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study. * Participant is willing and able to provide written informed consent. Exclusion Criteria: * Contraindications per the Vanquish IFU * Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.